A few years ago, a buddy of mine from business school invited me to a fancy dinner at his Manhattan brownstone. By the time I finished my first glass of Champagne, I’d met most of the guests — a mix of money managers, venture capitalists, and private equity heavyweights.
While the world obsesses over the next AI model, a quieter but equally ambitious race is underway: the race to slow, stop, or reverse aging itself. This market is called longevity biotech, and billions of investment dollars are pouring into it.
When it comes to making money for my readers — or saving them from losses — I love being able to say, “I told you so!” Back on June 17 th , I told Crowdability readers to sit out the SpaceX IPO frenzy.
This year has been nuts. The venture-capital world has been throwing around numbers that sound like typos: OpenAI landed a funding round worth $122 billion.
There you were, scrolling through stock tickers this week, and boom — you saw SpaceX (SPCX) exploding higher. After the biggest IPO in history, Elon’s rocket company is now valued at about $2.6 trillion.